Injectable PrEP Offers Hope Against HIV, But Costs Could Prevent Its Use In Africa

The New York Times (9/27, Nolen) reports a clinical trial of cabotegravir has found the “injectable PrEP to be a huge success, nearly eliminating women’s risk of contracting H.I.V., and to be 88 percent more effective than the daily pill.” The injectable...